ANALYSIS OF LIPID PROFILES AND HEMATOLOGICAL PARAMETERS IN INDIVIDUALS WITH HYPERTENSION

Main Article Content

Nabila Asif
Bushra Anwar
Iram Manzoor
Amna Hussain
Rafia Siddiqui
Syeda Asiya Parveen

Keywords

Hypertension, Dyslipidemia, Lipid Profile, Hematological Parameters, Blood Pressure, Cardiovascular Risk

Abstract

Background: Hypertension is a prevalent cardiovascular condition associated with increased risk of morbidity and mortality. Dyslipidemia and altered hematological parameters are commonly observed in hypertensive patients and may exacerbate cardiovascular risk.


Objective: The primary objective was to assess the prevalence of dyslipidemia and abnormal hematological parameters in hypertensive patients and to evaluate their relationships with systolic and diastolic blood pressure.


Methods: A cross-sectional study was conducted at Fazaia Medical College Air University, Islamabad from January 2024 to June 2024 involving 135 hypertensive patients, who were recruited from a single healthcare facility. Lipid profiles, including total cholesterol, LDL-C, HDL-C, and triglycerides, were measured. Hematological parameters such as hemoglobin, hematocrit, white blood cell (WBC) count, and platelet count were also assessed. Correlation analyses were performed to determine the relationships between these parameters and blood pressure.


Results: The study population had a mean age of 55.6 ± 9.8 years. The mean total cholesterol level was 215.4 ± 38.2 mg/dL, with 59.3% of patients exhibiting elevated levels. LDL-C was elevated in 67.4% of patients, and 72.6% had low HDL-C levels. Triglyceride levels were elevated in 53.3% of patients. Hematological analysis revealed that 29.6% of patients had low hemoglobin levels, 23.7% had low hematocrit, 16.3% had elevated WBC counts, and 12.6% had elevated platelet counts. Significant positive correlations were found between LDL-C and systolic blood pressure (r = 0.42, p < 0.001), and negative correlations between HDL-C and diastolic blood pressure (r = -0.30, p = 0.002). Hematocrit levels showed a weak positive correlation with systolic blood pressure (r = 0.24, p = 0.012).


Conclusion: The study identified a high prevalence of dyslipidemia and abnormal hematological parameters among hypertensive patients. These abnormalities were significantly associated with variations in blood pressure levels.

Abstract 44 | Pdf Downloads 18

References

1. Sarki AM, Nduka CU, Stranges S, et al. Prevalence of hypertension in low- and middle-income countries: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(12)
2. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334-1357.
3. Cohen JB, Cohen DL. Integrating out-of-office blood pressure in the diagnosis and management of hypertension. JAMA. 2021;325(1):50-51.
4. Chen L, Huang J, Xie D, et al. The effects of dyslipidemia on hypertension: From the perspective of microcirculation. Clin Exp Hypertens. 2022;44(5):387-397.
5. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2021;371(9623):1513-1518.
6. Wang H, Ma R, Zhou W, et al. Lipid metabolism in hypertension: A comprehensive overview. Am J Physiol Heart Circ Physiol. 2023;324(2)
7. Borghi C, Tubach F, De Backer G, et al. LDL-cholesterol lowering efficacy and safety of statins in hypertensive patients: A meta-analysis. J Hypertens. 2020;38(7):1205-1214.
8. Ibrahim A, Abdalla A, Al Jabri N, et al. Hematological parameters in hypertensive patients: An insight into the pathophysiology of hypertension. Front Cardiovasc Med. 2023;10:112032.
9. Kumari S, Chandramohan P. Hematocrit and hypertension: A potential link for cardiovascular risk stratification. Curr Hypertens Rep. 2021;23(8):67.
10. Balasubramanian K, Singh N, Nandakumar R. Platelet aggregation and its clinical significance in hypertensive individuals: A systematic review. Thromb Res. 2023;216:118-123.
11. Vasan RS, Larson MG, Levy D. The progression from hypertension to heart failure: The role of lipid and hematological abnormalities. J Am Coll Cardiol. 2020;76(4):353-361.
12. Lee YH, Shin HJ, Cho Y. The role of inflammation and hematological factors in hypertension: A focus on recent findings. Hypertens Res. 2023;46(4):654-660.
13. Khan MS. Dyslipidemia in hypertensive patients: Prevalence and cardiovascular risk. J Hypertens. 2021;39(3):254-261.
14. Tanaka H,. Lipid profile abnormalities in hypertension: A comparative study. Clin Hypertens. 2022;28(5):123-129.
15. Egan BM, et al. Relationship between lipid levels and blood pressure control in hypertensive patients. J Am Coll Cardiol. 2020;75(11):1395-1403.
16. Yadav PK. Lipid profiles and their correlation with blood pressure in hypertensive patients. Int J Hypertens. 2023;2023:458234.
17. Anand S, et al. HDL cholesterol in hypertensive populations: A cross-sectional analysis. J Clin Lipidol. 2022;16(2):162-169.
18. Fatima A. Association of triglyceride levels with hypertension and metabolic syndrome. J Endocrinol Metab. 2021;15(4):412-418.
19. Prakash A, et al. Hemoglobin levels and anemia prevalence in hypertensive patients. Hypertens Res. 2023;46(1):55-61.
20. Zafar I. Inflammatory markers and blood pressure in hypertensive individuals. J Cardiovasc Res. 2020;14(3):301-308.
21. Abraham E. Platelet counts in hypertensive patients and the risk of thrombosis. Thromb Haemost. 2022;19(4):1024-1031.
22. Gupta N. Hematocrit levels and their association with blood pressure in hypertension. Blood Press. 2021;30(5):285-291.